Market closed
Edgewise Therapeutics/$EWTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Ticker
$EWTX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
110
Website
EWTX Metrics
BasicAdvanced
$1.9B
-
-$1.45
0.23
-
Price and volume
Market cap
$1.9B
Beta
0.23
52-week high
$35.66
52-week low
$14.90
Average daily volume
1.4M
Financial strength
Current ratio
19.928
Quick ratio
19.705
Long term debt to equity
0.815
Total debt to equity
1.032
Management effectiveness
Return on assets (TTM)
-24.01%
Return on equity (TTM)
-34.40%
Valuation
Price to book
4.16
Price to tangible book (TTM)
4.16
Price to free cash flow (TTM)
-16.86
Growth
Earnings per share change (TTM)
-7.88%
3-year earnings per share growth (CAGR)
8.27%
What the Analysts think about EWTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Edgewise Therapeutics stock.
EWTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
EWTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
EWTX News
AllArticlesVideos
Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On
Seeking Alpha·10 hours ago
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
Benzinga·14 hours ago
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
Investors Business Daily·17 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Edgewise Therapeutics stock?
Edgewise Therapeutics (EWTX) has a market cap of $1.9B as of April 03, 2025.
What is the P/E ratio for Edgewise Therapeutics stock?
The price to earnings (P/E) ratio for Edgewise Therapeutics (EWTX) stock is 0 as of April 03, 2025.
Does Edgewise Therapeutics stock pay dividends?
No, Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders as of April 03, 2025.
When is the next Edgewise Therapeutics dividend payment date?
Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Edgewise Therapeutics?
Edgewise Therapeutics (EWTX) has a beta rating of 0.23. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.